Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company, Wednesday announced that it has appointed Terrie Kellmeyer as its Interim Chief Executive Officer.
Kellmeyer will be taking over from Christopher Missling who departed from the company on April 30.
Terrie Kellmeyer is the company's incumbent Senior Advisor and former Senior Vice President of Clinical Development. He has nearly three decades of experience across the full spectrum of drug development and has served as the Department Head for Global Regulatory Affairs, Clinical Development, Clinical Operations, Safety, Quality Assurance and Medical Affairs at numerous healthcare companies.
In pre-market activity, AVXL shares were trading at $3.45, up 2.68% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.